{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:03:51Z","timestamp":1764306231899,"version":"build-2065373602"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41591-025-03959-2","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:03:43Z","timestamp":1757495023000},"page":"3290-3291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Critical evaluation of the ProfiLER-02 study design and outcomes"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"3959_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","volume":"31","author":"O Tr\u00e9dan","year":"2025","unstructured":"Tr\u00e9dan, O. et al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. Nat. Med. 31, 1502\u20131508 (2025).","journal-title":"Nat. Med."},{"key":"3959_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744\u2013750 (2019).","journal-title":"Nat. Med."},{"key":"3959_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"3959_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrclinonc.2016.164","volume":"13","author":"C Le Tourneau","year":"2016","unstructured":"Le Tourneau, C. & Kurzrock, R. What have we learned from SHIVA? Nat. Rev. Clin. Oncol. 13, 719\u2013720 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3959_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"3959_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks, L. E. L. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Prim. 10, 71 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"3959_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3959_CR8","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.22.02833","volume":"41","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. & Kurzrock, R. Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J. Clin. Oncol. 41, 3100\u20133103 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3959_CR9","unstructured":"Fletcher, L. The $100 genome: where\u2019s the limit? https:\/\/frontlinegenomics.com\/the-100-genome-wheres-the-limit\/ (2025)."},{"key":"3959_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60369-1","volume":"16","author":"V Subbiah","year":"2025","unstructured":"Subbiah, V. Tissue-agnostic cancer therapies: promise, reality, and the path forward. Nat. Commun. 16, 4972 (2025).","journal-title":"Nat. Commun."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03959-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03959-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03959-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:04:21Z","timestamp":1760623461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03959-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3959"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03959-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"type":"print","value":"1078-8956"},{"type":"electronic","value":"1546-170X"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.S. reports research funding for clinical trials paid to the institution from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrix, Eli Lilly\/Loxo Oncology, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche\/Genentech, Takeda and Turning Point Therapeutics; consulting\/advisory role (paid to institution) from AbbVie, Astex Pharmaceuticals, AstraZeneca, Bayer, Genmab, Incyte, Lilly\/Loxo Oncology, Novartis, Obsidian Therapeutics, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Roche, Endeavor Biomedicines, RevMed and LabGenius therapeutics; and other consulting\/advisory role\/CME from Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology\/Lilly, Novartis, Relay Therapeutics, Daiichi Sankyo, Illumina, Bayer, Medscape, OncLive, Clinical Care Communications, PERS and Med learning group. R.K. has received research funding from Biological Dynamics, Boehringer, Caris, Datar Genomics, Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant and\/or speaker fees and\/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, F. Hoffmann-La Roche AG, TD2\/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch, CureMetrix and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch. The content is solely the responsibility of the authors and does not necessarily represent the official views of the institutions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}